Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?

BACKGROUND. The US Food and Drug Administration authorized Convalescent Plasma (CCP) therapy for hospitalized COVID-19 patients via the Expanded Access Program (EAP) and the Emergency Use Authorization (EUA), leading to use in about 500,000 patients during the first year of the pandemic for the US....

Descripción completa

Detalles Bibliográficos
Autores principales: Casadevall, Arturo, Dragotakes, Quigly, Johnson, Patrick W., Senefeld, Jonathon W., Klassen, Steven A., Wright, R. Scott, Joyner, Michael J, Paneth, Nigel, Carter, Rickey E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043483/
https://www.ncbi.nlm.nih.gov/pubmed/33851186
http://dx.doi.org/10.1101/2021.04.07.21255089

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8043483/
https://www.ncbi.nlm.nih.gov/pubmed/33851186
http://dx.doi.org/10.1101/2021.04.07.21255089

Ejemplares similares